Home Compare QIA.DE vs REGN
Stock Comparison · Structural lead, mixed market

Qiagen N.V. vs Regeneron Pharmaceuticals: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Qiagen carrying a narrow edge on growth. Regeneron Pharmaceuticals still has the edge on valuation, which keeps the comparison from looking entirely one-sided. In the market, Regeneron Pharmaceuticals carries the stronger setup — intact trend against Qiagen's broken trend. That leaves a split case: the structural lead stays with Qiagen, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The lead is spread across growth and stability, rather than sitting in one isolated gap.

Trajectory Similarity
0.66
Moderately similar
Peer-set rank: #3
within Qiagen N.V.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

Most of the shared profile comes through operating margin level and revenue stability.

Similarity drivers
operating margin levelrevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
QIA.DE
Qiagen N.V.
62
Peer-Score
Signal qualityHigh
vs
REGN
Regeneron Pharmaceuticals, Inc.
61
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: QIA.DE vs REGN Profitability 59 63 Stability 83 65 Valuation 62 80 Growth 44 22 QIA.DE REGN
Gap Ranking
#1 Growth +22
#2 Valuation +18
#3 Stability +18
#4 Profitability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for QIA.DE and REGN Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer QIA.DEREGN Relative valuation Structural strength

Qiagen N.V. looks stronger, but the price setup still looks more supportive for Regeneron Pharmaceuticals, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Qiagen N.V. holds the stronger peer position on growth.
Valuation
Both rank well on valuation, but Regeneron Pharmaceuticals, Inc. still holds a clear edge.
Growth — Dominant Gap
QIA.DE
44
REGN
22
Gap+22in favour of QIA.DE

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

There is still a strong counterforce in valuation, so the lead stays clear without becoming a sweep.

What this means for the comparison

The lead is built on both growth and valuation — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the QIA.DE vs REGN comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-valuation comparisons

Explore how QIA.DE and REGN each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.